Navigating Medicare Skyrizi Prior Authorization

Skyrizi's Indications and Medicare Coverage Nuances

Skyrizi (risankizumab) is indicated for moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's disease. Determining the correct Medicare benefit — Part B or Part D — is fundamental for prior authorization routing. Skyrizi is primarily a self-administered biologic, falling under the Medicare Part D (pharmacy benefit) umbrella. However, initial loading doses or specific clinical scenarios where the drug is administered in an outpatient clinic setting might trigger Part B coverage considerations, requiring distinct prior authorization pathways.

Medicare Part D Prior Authorization Framework

Most Medicare Skyrizi prior authorization requests will route through a patient’s Medicare Part D plan, whether a Prescription Drug Plan (PDP) or a Medicare Advantage Prescription Drug (MA-PD) plan. These plans establish their own formularies and utilization management criteria, including prior authorization, step therapy, and quantity limits. CMS mandates that Part D plans provide an electronic prior authorization (ePA) process, which aims to standardize and accelerate review times. Understanding the specific PBM (e.g., OptumRx, Express Scripts, CVS Caremark) managing the Part D benefit is crucial, as each maintains its own portal and submission requirements.

Common Clinical Criteria for Skyrizi Authorization

Payer prior authorization criteria for Skyrizi typically align with FDA-approved indications and established clinical guidelines. Common requirements include a confirmed diagnosis (supported by ICD-10 codes), documentation of disease severity, and evidence of prior treatment failures. Step therapy protocols often require trials of less costly alternatives, such as methotrexate or other TNF inhibitors, before Skyrizi is approved. Clinical notes must clearly articulate the patient’s condition, previous treatments, and the medical necessity for Skyrizi, often referencing criteria from sources like MCG or InterQual.

Leveraging Electronic Prior Authorization (ePA) Standards

The transition to electronic prior authorization is critical for efficiency. The X12 278 (HIPAA) transaction set remains the standard for medical benefit prior authorization, while NCPDP SCRIPT is the standard for pharmacy benefit (Part D) ePA. The CMS-0057-F final rule, effective January 1, 2026, mandates that Part D plans implement an electronic prior authorization process that leverages the NCPDP SCRIPT standard. Furthermore, the Da Vinci PAS (Prior Authorization Support) implementation guide, built on SMART on FHIR, seeks to integrate clinical data directly from EMRs into the ePA process, reducing manual data entry and speeding up determinations.

Key Data Elements for Skyrizi ePA Submissions

• Patient demographics and insurance information (Medicare Part D details)
• Skyrizi NDC (National Drug Code) and prescribed dosage/frequency
• Primary and secondary ICD-10 diagnosis codes
• Relevant CPT codes for administration, if applicable (for Part B scenarios)
• Documentation of prior treatment failures (e.g., methotrexate, other biologics)
• Objective clinical findings and severity scores (e.g., PASI, CDAI, BSA)
• Attestation of contraindications absence

Integrating ePA Workflows with EMR Systems

Effective Medicare Skyrizi prior authorization management requires robust integration between EMR systems (e.g., Epic Hyperspace, Cerner PowerChart) and ePA platforms (e.g., CoverMyMeds, Surescripts, Availity). EMR integration leads must ensure that clinical data can be extracted and transmitted efficiently to populate ePA requests. Challenges often include mapping EMR data fields to payer-specific questions and managing the varied submission pathways across different Part D plans and their PBMs. A well-configured integration minimizes manual re-entry, reduces errors, and accelerates the submission cycle.

Operational Strategies for PA Teams

Revenue cycle and prior authorization teams must adopt proactive strategies to manage Skyrizi requests. This includes verifying patient eligibility and formulary coverage early in the prescribing process. Dedicated prior authorization coordinators should be well-versed in Medicare Part D policies and payer-specific criteria. Establishing standardized documentation templates and workflows helps ensure all necessary clinical information is captured upfront. For denials, a clear appeals process, including preparing for peer-to-peer (P2P) reviews, is essential for overturning unfavorable determinations.